<div id="readability-page-1"><div> <p>CSPC PHARMA (01093.HK)<span> </span><span> -0.180 (-2.419%)  </span> <span> Short selling $117.62M; Ratio 20.387%  </span>  announced its results for 1Q26 ended March. Revenue amounted to RMB6.465 billion, down 7.8% YoY. Net profit was RMB860 million, down 41.8% YoY; EPS was RMB0.0754.<br/></p><br/>During the period, excluding fair value changes of financial assets at fair value through profit or loss and share-based employee compensation expenses, basic profit attributable to shareholders was RMB842 million, down 40.3% YoY.<p>In 1Q26, revenue from the finished drug business was RMB5.224 billion (including licensing fee income of RMB146 million), down 5% YoY, mainly due to a decrease in licensing fee income during the period. The decline in licensing fee income was primarily because, pursuant to the terms and conditions of relevant exclusive licensing agreements, the company recognized upfront payments totaling USD100 million as revenue in the same period last year.</p><p>R&amp;D expenses increased 7.7% YoY to RMB1.403 billion, accounting for 26.8% of finished drug business revenue. Currently, more than 130 products are at various stages of development, among which applications for marketing approval covering 11 indications have been submitted, and nearly 30 key products are in the registered clinical stage. (sl/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-05-26 16:25.)</p><p>AASTOCKS Financial News</p> </div></div>

01093

159506

562050

<p>CSPC PHARMA reported a 40.3% YoY decline in basic profit for 1Q26, totaling RMB842 million. Revenue fell 7.8% YoY to RMB6.465 billion, with net profit down 41.8% to RMB860 million. The finished drug business generated RMB5.224 billion, a 5% decrease YoY, largely due to reduced licensing fee income. R&D expenses rose 7.7% YoY to RMB1.403 billion, representing 26.8% of finished drug revenue.</p>

CSPC PHARMA 1Q26 Basic Profit Falls 40.3% YoY to RMB842 million